IP Library › Assignment 028363/0040
Patent Assignment
Reel/Frame 028363/0040

Security Agreement

Recorded: 2012-06-12 Pages: 11
Assignor
SAVIENT PHARMACEUTICALS, INC.
Executed: 2012-05-09
Assignee
MORGAN STANLEY SENIOR FUNDING INC.
1 PIERREPONT PLAZA, 7TH FLOOR, BROOKLYN, NEW YORK, 11201
Covered Properties (59)
A Variant Form of Urate Oxidase and Use Thereof
Variant Forms of Urate Oxidase and Use Thereof
Purification of Proteins with Cationic Surfactant
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Methods for Assessing Tophus Response During Urate Lowering Therapy in Treatment Tophaceous Gout
Plasmids for Expression and Method of Producing a Human Manganese Superoxide Dismutase Analog
Patent: 5,270,195 →
Application: 07/912,213 →
Method for Purification of Recombinant Copper/Zinc (Cu-Zn) Superoxide Dismutase from Bacteria or Eucaryotic Cells
Patent: 5,360,729 →
Application: 08/029,030 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 5,455,158 →
Application: 08/058,241 →
Expression Plasmids Regulated by an Osmb Promoter
Patent: 5,795,776 →
Application: 08/216,851 →
Method for Ameliorating Muscle Weakness/Wasting in a Patient Infected with Human Immunodeficiency Virus-Type 1
Patent: 6,090,799 →
Application: 08/244,988 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 5,679,320 →
Application: 08/259,569 →
Expression Plasmids Containing the Deo Promoter, and Bacterial Hosts Containing the Plasmids
Patent: 5,593,860 →
Application: 08/261,750 →
Human Manganese Superoxide Dismutase Dna, Its Expression and Method of Recovering Human Manganese Superoxide Dismutase
Patent: 6,610,520 →
Application: 08/299,047 →
Plasmids for Production of Human Growth Hormone or Polypeptide Analog Thereof, Hosts Containing the Plasmids, Products Manufactured Thereby, and Related Methods
Patent: 5,637,495 →
Application: 08/340,045 →
Contraception System and Method
Patent: 35,724 →
Application: 08/369,309 →
Methods of Use of Human Manganese Superoxide Dismutase
Patent: 5,540,911 →
Application: 08/370,461 →
Method of Removing N-Terminal Amino Acid Residues from Eucaryotic Polypeptide Analogs and Polypeptides Produced Thereby
Patent: 5,763,215 →
Application: 08/400,544 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 5,965,383 →
Application: 08/409,750 →
Expression Vectors Containing Lambda Pl Promoter and T1 T2 Rrna Termination Sequence Plasmids Containing the Vectors Hosts Containing the Plasmids and Related Methods
Patent: 5,759,816 →
Application: 08/450,014 →
Plasmids for Expression of Human Superoxide Dismutase (Sod) Analogs Containing Lambda Pl Promoter with Engineered Restriction Site for Substituting Ribosomal Binding Sites, Sod Analogs, Methods of Recovery and Uses Thereof
Patent: 6,030,611 →
Application: 08/451,474 →
Bacterial Expression of Superoxide Dismutase
Patent: 5,670,371 →
Application: 08/459,356 →
Expression Plasmids Containing the Deo Promoter, and Bacterial Hosts Containing the Plasmids
Patent: 6,010,875 →
Application: 08/686,465 →
Human Manganese Superoxide Dismutase Dna, Its Expression and Method of Recovering Human Managanese Superoxide Dismutase
Patent: 6,361,772 →
Application: 08/686,466 →
Production of Enzymatically Active Recombinant Carboxypeptidase B
Patent: 5,948,668 →
Application: 08/782,760 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 5,869,616 →
Application: 08/826,885 →
Expression Vectors for Enhanced Production of Polypeptides, Plasmids Containing the Vectors, Host Containing the Plasmids, Products Manufactured Thereby and Related Methods
Patent: 6,054,291 →
Application: 08/871,302 →
Expression Plasmids Regulated by an Osmb Promoter
Patent: 5,945,304 →
Application: 08/897,043 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 6,121,426 →
Application: 08/909,140 →
Refolding of Proinsulins Without Addition of Reducing Agents
Patent: 6,001,604 →
Application: 08/967,867 →
Use of Oxandrolone in the Treatment of Burns and Other Wounds
Patent: 6,576,659 →
Application: 08/985,734 →
Use of Oxandrolone in the Treatment of Chronic Obstructive Pulmonary Disease
Patent: 5,872,147 →
Application: 08/986,015 →
Method for Ameliorating Muscle Weakness/Wasting in a Patient Infected with Human Immunodeficiency Virus-Type 1
Patent: 6,670,351 →
Application: 09/469,817 →
Fibrin Binding Domain Polypeptides and Uses and Methods of Producing Same
Patent: 7,087,722 →
Application: 09/492,971 →
Use of Oxandrolone in the Treatment of Burns and Other Wounds
Patent: 6,828,313 →
Application: 10/011,377 →
Publication: US 2002/0165266
Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
Application: 10/052,961 →
Publication: US 2002/0091155
Use of Oxandrolone in the Treatment of Burns and Other Wounds
Patent: 8,026,274 →
Application: 10/799,197 →
Publication: US 2004/0171673
Use of Oxandrolone in the Treatment of Burns and Other Wounds
Patent: 8,053,425 →
Application: 10/799,264 →
Publication: US 2004/0235940
Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of Peg-Uricase
Patent: 8,148,123 →
Application: 11/539,475 →
Publication: US 2007/0274977
Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
Application: 11/726,105 →
Publication: US 2007/0254029
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
Application: 11/899,688 →
Publication: US 2008/0159976
Purification of Proteins With Cationic Surfactant
Patent: 9,534,013 →
Application: 11/918,292 →
Publication: US 2009/0317889
Variant Form of Urate Oxidase and Use Thereof
Patent: 7,811,800 →
Application: 11/918,296 →
Publication: US 2009/0209021
Variant Forms of Urate Oxidase and Use Thereof
Patent: 8,188,224 →
Application: 11/918,297 →
Publication: US 2009/0169534
Variant Form of Urate Oxidase and Use Thereof
Patent: 7,964,381 →
Application: 12/879,084 →
Publication: US 2011/0104751
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,034,594 →
Application: 13/107,498 →
Publication: US 2011/0217755
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,178,334 →
Application: 13/226,891 →
Publication: US 2012/0070876
Use Of Oxandrolone In The Treatment Of Burns And Other Wounds
Application: 13/242,246 →
Publication: US 2012/0015875
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Patent: 9,377,454 →
Application: 13/379,704 →
Publication: US 2012/0301454
Methods for Assessing Tophus Response During Urate Lowering Therapy in Treatment Tophaceous Gout
Application: 13/379,719 →
Publication: US 2012/0323107
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,293,228 →
Application: 13/452,151 →
Publication: US 2012/0225046
Variant Forms of Urate Oxidase and Use Thereof
Patent: 8,541,205 →
Application: 13/461,170 →
Publication: US 2012/0309085
Purification of proteins with cationic surfactant
Application: 60/670,520 →
Variant form of urate oxidase and use thereof
Application: 60/670,541 →
Variant forms of urate oxidase and use thereof
Application: 60/670,573 →
First Application of Computer-Assisted Analysis of Digital Photographs for Assessing Tophus Response: Phase 3 Studies of Pegloticase in Treatment Failure Gout
Application: 61/248,680 →
Routine Serum Uric Acid (SUA) Monitoring Predicts Antibody-Mediated Loss of Response and Infusion Reaction Risk During Pegloticase Therapy
Application: 61/248,698 →
Methods for Assessing Tophus Response During Pegloticase Therapy in Treatment Failure Gout
Application: 61/261,589 →
Developments related to the treatment of gout
Application: 61/269,669 →
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegloticase Therapy
Application: 61/298,718 →
Related Assignments (23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignors Interest. Nov 7, 1989
From: LIFSHITZ, RUTH; HADARY, DANY
To: BIO-TECHNOLOGY GENERAL CORP.
Reel/Frame 005174/0633 →
Assignment of Assignor's Interest Jun 20, 1994
From: BERGER, JOSEPH R.
To: BTG PHARMACEUTICALS CORP.
Reel/Frame 007697/0179 →
Assignment of Assignor's Interest Sep 14, 1994
From: FISCHER, MEIR
To: BIO-TECHNOLOGY GENERAL CORP.
Reel/Frame 007132/0655 →
Merger Jan 11, 1996
From: GYNEX PHARMACEUTICALS, INC.
To: BTG ACQUISITION SUBSIDIARY, INC.
Reel/Frame 007769/0067 →
Change of Name Jan 11, 1996
From: BTG ACQUISITION SUBSIDIARY, INC.
To: BTG PHARMACEUTICALS CORP.
Reel/Frame 007769/0073 →
Merger Dec 6, 1996
From: BTG PHARMACEUTICALS CORPORATION
To: BIO-TECHNOLOGY GENERAL CORP.
Reel/Frame 008262/0685 →
Assignment of Assignor's Interest Sep 14, 1998
From: GONENNE, AMNON
To: BIO-TECHNOLOGY GENERAL CORP.
Reel/Frame 009457/0292 →
Merger & Change of Name Feb 14, 2000
From: BTG PHARMACEUTICALS CORP.
To: BIO-TECHNOLOGY GENERAL CORP.
Reel/Frame 010615/0799 →
Change of Name Jan 16, 2004
From: BIO-TECHNOLOGY GENERAL CORP.
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 014871/0808 →
Change of Name Jun 21, 2004
From: BIO-TECHNOLOGY GENERAL CORP.
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 014754/0469 →
Assignment of Assignor's Interest Sep 14, 2012
From: CORELAB PARTNERS, INC.
To: FORD, ROBERT
Reel/Frame 028961/0992 →
Corrective Assignment to Correct the Receiving Party Previously Recorded on Reel 028363 Frame 0040. Assignor(S) Hereby Confirms the Security Agreement. Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
Security Agreement Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →
Security Agreement Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
Release of Security Interest Aug 10, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: SAVIENT PHARMA HOLDINGS, INC.
Reel/Frame 036316/0906 →
Release of Security Interest Aug 10, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: SAVIENT PHARMACEUTICAL, INC.
Reel/Frame 036317/0049 →
Release of Security Interest Aug 11, 2015
From: JEFFERIES FINANCE LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036296/0750 →
Assignment of Assignor's Interest Aug 11, 2015
From: CREALTA PHARMACEUTICALS LLC
To: GEMINI LABORATORIES LLC
Reel/Frame 036297/0453 →
Release of Security Interest Aug 11, 2015
From: FIFTH STREET FINANCE CORP.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036297/0163 →
Assignment of Assignor's Interest Aug 11, 2015
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036328/0001 →
Corrective Assignment to Correct the Receiving Party Data Previously Recorded at Reel: 036297 Frame: 0453. Assignor(S) Hereby Confirms the Assignment. Apr 26, 2016
From: CREALTA PHARMACEUTICALS LLC
To: GEMINI LABORATORIES, LLC
Reel/Frame 038523/0263 →
Release of Security Interest Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
Assignment of Assignor's Interest Nov 6, 2023
From: CLARK, DAVID G.
To: FLORIDA FOUNDATION SEED PRODUCERS, INC.
Reel/Frame 065476/0440 →